drug · small molecule
patient view →lazertinib mesylate
Marketedupdated 2mo agoby $JNJ JOHNSON & JOHNSON🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for non-small cell lung carcinoma and 1 investigational indication.
indications
investigational
NSCLC
targets
Epidermal growth factor receptor
all catalysts(3)
approval · 3
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that